Dongyao Yan serves as a Clinical Development Lead at Roche, where she leverages her extensive expertise in translational oncology to drive innovative research and development initiatives. With a robust background in precision medicine and biomarker development, Dongyao is at the forefront of addressing unmet medical...
Dongyao Yan serves as a Clinical Development Lead at Roche, where she leverages her extensive expertise in translational oncology to drive innovative research and development initiatives. With a robust background in precision medicine and biomarker development, Dongyao is at the forefront of addressing unmet medical needs in oncology. Her role involves leading translational and early-concept biomarker research that enhances the understanding of cancer patient journeys, ultimately contributing to the expansion of Roche Diagnostics' portfolio.
Throughout her career, Dongyao has successfully delivered over ten clinical biomarker studies, showcasing her ability to manage complex projects from conception to execution. Her 13 years of experience in medical scientific Key Opinion Leader (KOL) engagement have been pivotal in fostering over 15 research collaborations, ensuring that Roche remains aligned with cutting-edge advancements in cancer biology and treatment modalities.
In her current position, she collaborates with cross-functional teams to deliver analytical and clinical performance studies, ensuring that Roche's diagnostic solutions meet the highest standards of efficacy and compliance. Dongyao's proficiency in techniques such as ELISA, immunohistochemistry, and PCR, combined with her knowledge of tumor immunology and molecular biology, empowers her to translate bench research into meaningful clinical applications. By identifying and partnering with leading KOLs, she executes a comprehensive medical value strategy that not only enhances patient outcomes but also positions Roche as a leader in the evolving landscape of oncology diagnostics.
